2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-105919
    Naroparcil 120819-70-7 98%
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration.
    Naroparcil
  • HY-105925
    Mefenidil 58261-91-9 98%
    Mefenidil (MCN 2378) is a selective cerebral vasodilator that is not affected by beta-adrenergic blockade. Mefenidil can be used in the study of cardiovascular disease. In monkey models, mefenidil preferentially increases cerebral blood flow over systemic (femoral) blood flow. Mefenidil is also able to reduce systemic arterial pressure in anesthetized dogs.
    Mefenidil
  • HY-105929
    Lorajmine 47562-08-3 98%
    Lorajmine (17-Monochloroacetylajmaline) is an Ajmaline (HY-B1167) (Sodium channel blocker) prodrug.
    Lorajmine
  • HY-105940
    IQB-782 40454-21-5 98%
    IQB-782 is a cysteine derivative. IQB-782 has inhibition for thrombin activatable fibrinolysis inhibitor (TAFI), with an Ki(app) of 0.14 μM. IQB-782 shows a potent mucolytic-expectorant activity.
    IQB-782
  • HY-105960
    Fenmetozole 41473-09-0 98%
    Fenmetozole is an antagonist of ethanol, and also antagonizes α2-adrenergic receptor, which has antidepressant effect.
    Fenmetozole
  • HY-106049
    Acrihellin 67696-82-6 98%
    Acrihellin is a type of cardiac-active steroid. Acrihellin can increase the contractility of the left atrium in guinea pigs.
    Acrihellin
  • HY-106066
    Dazmegrel 76894-77-4 98%
    Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research.
    Dazmegrel
  • HY-106080
    Furegrelate 85666-24-6 98%
    Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent.
    Furegrelate
  • HY-106088
    Tibenelast free acid 97852-72-7 98%
    Tibenelast (LY186655) free acid is a potent and orally active is a phosphodiesterase inhibitor. Tibenelast free acid is an anti-asthma agent Tibenelast free acid increases the heart rate response to isoproterenol (HY-108353). Tibenelast free acid shows anti-anaphylactic shock activity. Tibenelast free acid has the potential for the research of asthma and other respiratory diseases.
    Tibenelast free acid
  • HY-106102
    [Deglycinamide9, Arginine8]-Vasopressin 37552-33-3 98%
    [Deglycinamide9, Arginine8]-Vasopressin is a Vasopressin (HY-B1811) analog. [Deglycinamide9, Arginine8]-Vasopressin induces platelet aggregation. [Deglycinamide9, Arginine8]-Vasopressin has hemostatic effect.
    [Deglycinamide9, Arginine8]-Vasopressin
  • HY-106103
    Seglitide 81377-02-8 99.30%
    Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes.
    Seglitide
  • HY-106113
    Ditekiren 103336-05-6 98%
    Ditekiren (U 71038) is a pseudohexapeptide renin inhibitor. Renin is an enzyme that plays a crucial role in regulating blood pressure and fluid balance. By inhibiting the activity of renin, ditekiren slows down the formation of angiotensin II, a potent vasoconstrictor that can raise blood pressure. Ditekiren can be used for research in the field of blood pressure reduction.
    Ditekiren
  • HY-106115
    Vintoperol 106498-99-1 98%
    Vintoperol (RGH 2981; RT-3003) is a potent and orally active antithrombotic agent. Vintoperol interferes with platelet aggregation and has antithrombotic effects, protecting mice from retrograde and anterograde amnesia induced by traumatic brain injury.
    Vintoperol
  • HY-106123
    Pomisartan 144702-17-0 98%
    Pomisartan is an orally active angiotensin II receptor type AT1 antagonist (IC50=0.26 μM). Pomisartan works by inhibiting the binding of angiotensin II to the AT1 receptor, thereby blocking the vasoconstriction and aldosterone release caused by this interaction. Pomisartan results in a blood pressure-lowering effect.
    Pomisartan
  • HY-106206
    AL-6598 170291-06-2 98%
    AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research.
    AL-6598
  • HY-106207
    Celivarone 401925-43-7 98%
    Celivarone (SSR149744C) is a orally active noniodinated benzofuran derivative with antiarrhythmic properties. Celivarone has the potential for atrial fibrillation and in ventricular arrhythmias research.
    Celivarone
  • HY-106234
    ZP 120C 383123-18-0 98%
    ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia.
    ZP 120C
  • HY-106398
    MED 27 104333-87-1
    MED 27 is an inhibitor of thromboxane synthase and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of acetylsalicylic acid (HY-14654).
    MED 27
  • HY-106416
    Neldazosin 109713-79-3 98%
    Neldazosin is a potent alpha1-adrenoceptor antagonist.
    Neldazosin
  • HY-106428
    Icrocaptide 169543-49-1 98%
    Icrocaptide (ITF1697) is a stable Lys-Pro-containing peptide that inhibits the intracellular Ca2+-dependent fusion of Weibel-Palade bodies with the plasma membrane. Icrocaptide exerts its activity at the early stages of endothelial activation and inhibits P-selectin and von Willebrand factor secretion. Icrocaptide can be used for the study of a variety of microvascular disorders.
    Icrocaptide
Cat. No. Product Name / Synonyms Application Reactivity